Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Rating) – Zacks Small Cap reduced their FY2022 earnings per share estimates for shares of Lexaria Bioscience in a report released on Wednesday, August 3rd. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will earn ($1.21) per share for the year, down from their previous estimate of ($1.09). The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($1.09) per share.
Lexaria Bioscience Trading Up 1.5 %
Lexaria Bioscience stock opened at $2.83 on Friday. Lexaria Bioscience has a 52 week low of $1.85 and a 52 week high of $7.20. The stock has a 50 day moving average of $2.64 and a 200-day moving average of $3.06.
Institutional Investors Weigh In On Lexaria Bioscience
Lexaria Bioscience Company Profile
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others.
- Get a free copy of the StockNews.com research report on Lexaria Bioscience (LEXX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.